If you enjoy this content, please share it with a colleague
RELATED CONTENT
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one ...
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer ...
Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to a ...
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation ...
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S. regulators do as expected ...
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer today. While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new guideline addresses the appropriateness of SBRT for medically inoperable patients with high-risk clinical scenarios requiring curative focused therapy.
The American Society for Radiation Oncology (ASTRO) today announced an update to its Evidence-Based Consensus Statement for the use of Accelerated Partial Breast Irradiation (APBI) brachytherapy to include younger patients and those with low-risk ductal carcinoma in situ (DCIS).
As radiation therapy continues to evolve, new techniques and technologies are largely focused on maximizing the dose to the tumor site while protecting surrounding tissue as much as possible. Image guidance is a critical component of treatment planning for tumor delineation and gauging treatment response, and cone beam computed tomography (CBCT) has traditionally been the modality of choice.
Like with many other aspects of healthcare, technology has been the driving force behind the evolution of radiation therapy. New advancements have given rise to new, more precise techniques for delivering maximum radiation dose to tumor volumes with minimum effect to surrounding tissue.
The American Society for Radiation Oncology (ASTRO) recently welcomed Judy Keen, Ph.D., as its director of scientific affairs, a position created to grow research participation and collaboration in the field of radiation oncology.